Hyaluronidase fihj

Transplant Rejection

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkinsprotein_peptideEarly Phase 1Active

39/ 100

Provisional rating · Methodology v0.2

Rating breakdown

11 Active assets in the Transplant Rejection cohort.

Asset / Sponsor	Phase	Rating
Plerixafor Masonic Cancer Center, University of Minnesota	Phase 2	CCC
Cyclophosphamide Masonic Cancer Center, University of Minnesota	Phase 2	CCC
Sirolimus Masonic Cancer Center, University of Minnesota	Phase 2	CCC
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit Masonic Cancer Center, University of Minnesota	Phase 2	CCC
Fludarabine Masonic Cancer Center, University of Minnesota	Phase 2	CCC